Cargando…

Monitoring Response to Transarterial Chemoembolization in Hepatocellular Carcinoma Using (18)F-Fluorothymidine PET

Accurate disease monitoring is essential after transarterial chemoembolization (TACE) in hepatocellular carcinoma (HCC) because of the potential for profound adverse events and large variations in survival outcome. Posttreatment changes on conventional imaging can confound determination of residual...

Descripción completa

Detalles Bibliográficos
Autores principales: Sharma, Rohini, Inglese, Marianna, Dubash, Suraiya, Lu, Haonan, Pinato, David J., Sanghera, Chandan, Patel, Neva, Chung, Anthony, Tait, Paul D., Mauri, Francesco, Crum, William R., Barwick, Tara D., Aboagye, Eric O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Society of Nuclear Medicine 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8679631/
https://www.ncbi.nlm.nih.gov/pubmed/32513905
http://dx.doi.org/10.2967/jnumed.119.240598
_version_ 1784616567528488960
author Sharma, Rohini
Inglese, Marianna
Dubash, Suraiya
Lu, Haonan
Pinato, David J.
Sanghera, Chandan
Patel, Neva
Chung, Anthony
Tait, Paul D.
Mauri, Francesco
Crum, William R.
Barwick, Tara D.
Aboagye, Eric O.
author_facet Sharma, Rohini
Inglese, Marianna
Dubash, Suraiya
Lu, Haonan
Pinato, David J.
Sanghera, Chandan
Patel, Neva
Chung, Anthony
Tait, Paul D.
Mauri, Francesco
Crum, William R.
Barwick, Tara D.
Aboagye, Eric O.
author_sort Sharma, Rohini
collection PubMed
description Accurate disease monitoring is essential after transarterial chemoembolization (TACE) in hepatocellular carcinoma (HCC) because of the potential for profound adverse events and large variations in survival outcome. Posttreatment changes on conventional imaging can confound determination of residual or recurrent disease, magnifying the clinical challenge. On the basis of increased expression of thymidylate synthase (TYMS), thymidine kinase 1 (TK-1), and equilibrative nucleoside transporter 1 (SLC29A1) in HCC compared with liver tissue, we conducted a proof-of-concept study evaluating the efficacy of 3′-deoxy-3′-(18)F-fluorothymidine ((18)F-FLT) PET to assess response to TACE. Because previous PET studies in HCC have been hampered by high background liver signal, we investigated whether a temporal-intensity voxel clustering (kinetic spatial filtering, or KSF) improved lesion detection. Methods: A tissue microarray was built from 36 HCC samples and from matching surrounding cirrhotic tissue and was stained for TK-1. A prospective study was conducted; 18 patients with a diagnosis of HCC by the criteria of the American Association for the Study of Liver Diseases who were eligible for treatment with TACE were enrolled. The patients underwent baseline conventional imaging and dynamic (18)F-FLT PET with KSF followed by TACE. Imaging was repeated 6–8 wk after TACE. The PET parameters were compared with modified enhancement-based RECIST. Results: Cancer Genome Atlas analysis revealed increased RNA expression of TYMS, TK-1, and SLC29A1 in HCC. TK-1 protein expression was significantly higher in HCC (P < 0.05). The sensitivity of (18)F-FLT PET for baseline HCC detection was 73% (SUV(max), 9.7 ± 3.0; tumor to liver ratio, 1.2 ± 0.3). Application of KSF did not improve lesion detection. Lesion response after TACE by modified RECIST was 58% (14 patients with 24 lesions). A 30% reduction in mean (18)F-FLT PET uptake was observed after TACE, correlating with an observed PET response of 60% (15/25). A significant and profound reduction in the radiotracer delivery parameter K(1) after TACE was observed. Conclusion: (18)F-FLT PET can differentiate HCC from surrounding cirrhotic tissue, with PET parameters correlating with TACE response. KSF did not improve visualization of tumor lesions. These findings warrant further investigation.
format Online
Article
Text
id pubmed-8679631
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Society of Nuclear Medicine
record_format MEDLINE/PubMed
spelling pubmed-86796312022-01-05 Monitoring Response to Transarterial Chemoembolization in Hepatocellular Carcinoma Using (18)F-Fluorothymidine PET Sharma, Rohini Inglese, Marianna Dubash, Suraiya Lu, Haonan Pinato, David J. Sanghera, Chandan Patel, Neva Chung, Anthony Tait, Paul D. Mauri, Francesco Crum, William R. Barwick, Tara D. Aboagye, Eric O. J Nucl Med Oncology Accurate disease monitoring is essential after transarterial chemoembolization (TACE) in hepatocellular carcinoma (HCC) because of the potential for profound adverse events and large variations in survival outcome. Posttreatment changes on conventional imaging can confound determination of residual or recurrent disease, magnifying the clinical challenge. On the basis of increased expression of thymidylate synthase (TYMS), thymidine kinase 1 (TK-1), and equilibrative nucleoside transporter 1 (SLC29A1) in HCC compared with liver tissue, we conducted a proof-of-concept study evaluating the efficacy of 3′-deoxy-3′-(18)F-fluorothymidine ((18)F-FLT) PET to assess response to TACE. Because previous PET studies in HCC have been hampered by high background liver signal, we investigated whether a temporal-intensity voxel clustering (kinetic spatial filtering, or KSF) improved lesion detection. Methods: A tissue microarray was built from 36 HCC samples and from matching surrounding cirrhotic tissue and was stained for TK-1. A prospective study was conducted; 18 patients with a diagnosis of HCC by the criteria of the American Association for the Study of Liver Diseases who were eligible for treatment with TACE were enrolled. The patients underwent baseline conventional imaging and dynamic (18)F-FLT PET with KSF followed by TACE. Imaging was repeated 6–8 wk after TACE. The PET parameters were compared with modified enhancement-based RECIST. Results: Cancer Genome Atlas analysis revealed increased RNA expression of TYMS, TK-1, and SLC29A1 in HCC. TK-1 protein expression was significantly higher in HCC (P < 0.05). The sensitivity of (18)F-FLT PET for baseline HCC detection was 73% (SUV(max), 9.7 ± 3.0; tumor to liver ratio, 1.2 ± 0.3). Application of KSF did not improve lesion detection. Lesion response after TACE by modified RECIST was 58% (14 patients with 24 lesions). A 30% reduction in mean (18)F-FLT PET uptake was observed after TACE, correlating with an observed PET response of 60% (15/25). A significant and profound reduction in the radiotracer delivery parameter K(1) after TACE was observed. Conclusion: (18)F-FLT PET can differentiate HCC from surrounding cirrhotic tissue, with PET parameters correlating with TACE response. KSF did not improve visualization of tumor lesions. These findings warrant further investigation. Society of Nuclear Medicine 2020-12 /pmc/articles/PMC8679631/ /pubmed/32513905 http://dx.doi.org/10.2967/jnumed.119.240598 Text en © 2020 by the Society of Nuclear Medicine and Molecular Imaging. https://creativecommons.org/licenses/by/4.0/Immediate Open Access: Creative Commons Attribution 4.0 International License (CC BY) allows users to share and adapt with attribution, excluding materials credited to previous publications. License: https://creativecommons.org/licenses/by/4.0/. Details: http://jnm.snmjournals.org/site/misc/permission.xhtml.
spellingShingle Oncology
Sharma, Rohini
Inglese, Marianna
Dubash, Suraiya
Lu, Haonan
Pinato, David J.
Sanghera, Chandan
Patel, Neva
Chung, Anthony
Tait, Paul D.
Mauri, Francesco
Crum, William R.
Barwick, Tara D.
Aboagye, Eric O.
Monitoring Response to Transarterial Chemoembolization in Hepatocellular Carcinoma Using (18)F-Fluorothymidine PET
title Monitoring Response to Transarterial Chemoembolization in Hepatocellular Carcinoma Using (18)F-Fluorothymidine PET
title_full Monitoring Response to Transarterial Chemoembolization in Hepatocellular Carcinoma Using (18)F-Fluorothymidine PET
title_fullStr Monitoring Response to Transarterial Chemoembolization in Hepatocellular Carcinoma Using (18)F-Fluorothymidine PET
title_full_unstemmed Monitoring Response to Transarterial Chemoembolization in Hepatocellular Carcinoma Using (18)F-Fluorothymidine PET
title_short Monitoring Response to Transarterial Chemoembolization in Hepatocellular Carcinoma Using (18)F-Fluorothymidine PET
title_sort monitoring response to transarterial chemoembolization in hepatocellular carcinoma using (18)f-fluorothymidine pet
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8679631/
https://www.ncbi.nlm.nih.gov/pubmed/32513905
http://dx.doi.org/10.2967/jnumed.119.240598
work_keys_str_mv AT sharmarohini monitoringresponsetotransarterialchemoembolizationinhepatocellularcarcinomausing18ffluorothymidinepet
AT inglesemarianna monitoringresponsetotransarterialchemoembolizationinhepatocellularcarcinomausing18ffluorothymidinepet
AT dubashsuraiya monitoringresponsetotransarterialchemoembolizationinhepatocellularcarcinomausing18ffluorothymidinepet
AT luhaonan monitoringresponsetotransarterialchemoembolizationinhepatocellularcarcinomausing18ffluorothymidinepet
AT pinatodavidj monitoringresponsetotransarterialchemoembolizationinhepatocellularcarcinomausing18ffluorothymidinepet
AT sangherachandan monitoringresponsetotransarterialchemoembolizationinhepatocellularcarcinomausing18ffluorothymidinepet
AT patelneva monitoringresponsetotransarterialchemoembolizationinhepatocellularcarcinomausing18ffluorothymidinepet
AT chunganthony monitoringresponsetotransarterialchemoembolizationinhepatocellularcarcinomausing18ffluorothymidinepet
AT taitpauld monitoringresponsetotransarterialchemoembolizationinhepatocellularcarcinomausing18ffluorothymidinepet
AT maurifrancesco monitoringresponsetotransarterialchemoembolizationinhepatocellularcarcinomausing18ffluorothymidinepet
AT crumwilliamr monitoringresponsetotransarterialchemoembolizationinhepatocellularcarcinomausing18ffluorothymidinepet
AT barwicktarad monitoringresponsetotransarterialchemoembolizationinhepatocellularcarcinomausing18ffluorothymidinepet
AT aboagyeerico monitoringresponsetotransarterialchemoembolizationinhepatocellularcarcinomausing18ffluorothymidinepet